---
title: "US Stock Movement | Eli Lilly continues to hit historical highs, positive results from clinical research on new weight loss drugs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265553296.md"
description: "Eli Lilly rose nearly 3%, continuing to hit historical highs, with positive results from clinical research on new weight loss drugs"
datetime: "2025-11-12T14:59:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265553296.md)
  - [en](https://longbridge.com/en/news/265553296.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265553296.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/265553296.md) | [繁體中文](https://longbridge.com/zh-HK/news/265553296.md)


# US Stock Movement | Eli Lilly continues to hit historical highs, positive results from clinical research on new weight loss drugs

On November 12th (Wednesday), Eli Lilly rose nearly 3%, continuing to set a new historical high.

In terms of news:

Eli Lilly announced positive results from the Phase 2 clinical trial of its experimental weight loss drug eloralintide. At week 48, all dosage groups of eloralintide achieved the primary endpoint, with an average weight reduction of 9.5% to 20.1%, outperforming the placebo group's average reduction of 0.4% (using efficacy estimation targets). Based on these trial results, Eli Lilly will initiate enrollment for the Phase 3 clinical trial of eloralintide for obesity treatment next month

### Related Stocks

- [Eli Lilly and Company (LLY.US)](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

- [Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | LLY Stock News](https://longbridge.com/en/news/281171668.md)
- [InSilico Medicine's Loss Widens in 2025; Enters Licensing Agreement With Eli Lilly](https://longbridge.com/en/news/280951810.md)
- [Eli Lilly Says Long-Term Data Shows Eczema Treatment Provides Up to Four Years of Disease Control](https://longbridge.com/en/news/280800696.md)
- [Eli Lilly says Taltz and Zepbound met primary and all key secondary endpoints for statistical superiority to Taltz monotherapy at 36 weeks](https://longbridge.com/en/news/280886666.md)
- [Deals of the day-Mergers and acquisitions](https://longbridge.com/en/news/281036787.md)